|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | Ametycine | Storage (From the date of receipt) |
3 years -20°C(in the dark) powder | |||
| 化学式 | C15H18N4O5 |
||||||
| 分子量 | 334.37 | CAS No. | 50-07-7 | ||||
| Solubility (25°C)* | 体外 | DMSO | 67 mg/mL (200.37 mM) | ||||
| Water | Insoluble | ||||||
| Ethanol | Insoluble | ||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||
| 製品説明 | マイトマイシンC(アメチシン)は、DNA合成を阻害する抗悪性腫瘍性抗生物質であり、さまざまな癌の治療に用いられます。マイトマイシンCは、カスパーゼ依存性かつFas/CD95非依存性のメカニズムでアポトーシスを誘発します。本製品は危険有害性物質(急性毒性/引火性/皮膚腐食性)です。保護マスク、手袋、保護衣を着用してご使用ください。 |
|---|---|
| in vitro | Mitomycin C, by inducing DNA interstrand crosslinks, physically blocks DNA replication, recombination, and RNA transcription. This compound potentiates TRAIL-induced apoptosis in HCT116 (p53-/-) colon cancer cells and sensitizes TRAIL-resistant colon cancer cells HT-29 to the cytokine by through JNK-independent upregulation of death receptors. In different human cancer cell lines, such OVCAR-5 (ovary), HT-29 (colon), SK-N-MC (neuroblastoma), HEP-2 (liver), COLO-205 (colon), NIH-OVCAR-3 (ovary) and A-549 (lung) cells, this chemical shows cytotoxic activity. |
| in vivo | As the clinical first choice in superficial bladder tumors, in a rat bladder tumor model, Mitomycin C (400 μM) significantly prevents intravesical tumor growth. |
| 細胞アッセイ | 細胞株 | HCT116 cells |
|---|---|---|
| 濃度 | 5 µM | |
| 反応時間 | 24 h | |
| 実験の流れ | Cells were pre-treated with 5 µM MMC for 24 h and then co-treated with TRAIL (25 ng/mL). |
|
| 動物実験 | 動物モデル | Rat bladder tumor model |
| 投薬量 | 400 μM | |
| 投与方法 | Intravesical treatment |
|

Data from [Data independently produced by , , Cancer Sci, 2018, 109(11):3450-3460]
| An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis [ Cell, 2025, S0092-8674(25)00625-7] | PubMed: 40562027 |
| Nano-polymeric platinum activates PAR2 gene editing to suppress tumor metastasis [ Biomaterials, 2025, 317:123090] | PubMed: 39799696 |
| Structural basis of Fanconi anemia pathway activation by FANCM [ EMBO J, 2025, 44(14):4013-4036] | PubMed: 40447800 |
| Efficient derivation of stable sheep embryonic stem cells opens a new avenue for agricultural and biomedical application [ J Adv Res, 2025, S2090-1232(25)00565-X] | PubMed: 40712808 |
| ARRB2 promotes cervical cancer progression via stabilizing CDC25A mRNA through m6A-IGF2BP1-dependent manner [ NPJ Precis Oncol, 2025, 9(1):80] | PubMed: 40119070 |
| Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer [ Cell Death Discov, 2025, 11(1):423] | PubMed: 40998801 |
| Mechanism of hsa_circ_0069443 promoting early pregnancy loss through ALKBH5/FN1 axis in trophoblast cells [ iScience, 2025, 28(1):111608] | PubMed: 39868042 |
| PDLIM3 Regulates Migration and Invasion of Head and Neck Squamous Cell Carcinoma via YAP-Mediated Epithelial-Mesenchymal Transition [ Int J Mol Sci, 2025, 26(7)3147] | PubMed: 40243891 |
| GDF15 promotes the resistance of epithelial ovarian cancer cells to gemcitabine via DHCR24-mediated cholesterol metabolism to elevate ABCB1 and ABCC1 levels in lipid rafts [ Am J Cancer Res, 2025, 15(2):452-469] | PubMed: 40084368 |
| Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform [ Antib Ther, 2025, 8(1):1-12] | PubMed: 39839911 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。